BioSpace News Archive

Forge Therapeutics, Inc. announced that David Puerta, Ph.D., Forge’s COO and VP of Discovery, will discuss Forge’s emerging initiatives in antibacterial R&D in an oral presentation at the 28th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting being held April 21-24, 2018 in Madrid, Spain.

Henry Schein, Inc. announced that Mark Hillebrandt has joined the company in a newly created position, as Vice President, Marketing, North America Dental Group.

Charles River will provide clients access to PathoQuest’s NGS-based testing solutions

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced the appointment of Will McCarthy as chief business officer and Jennifer Elliott, Ph.D., J.D., as vice president, head of legal affairs and intellectual property.

Cydan announced that Imran A. Babar, PhD, has been named to the leadership team as chief business officer to help the company advance new and innovative therapies for patients living with rare monogenetic diseases.

Advises Shareholders That No Action Is Required at This Time

Dr. Laghrissi-Thode is currently on the Board of Directors for DalCor.

The Bloom2 stimulator is a fundamental component of nearly all electrophysiology (EP) procedures to diagnose and treat cardiac rhythm disorders.

Cancer Treatment Centers of America® (CTCA), a national network of comprehensive cancer care hospitals and outpatient care centers, and Foundation Medicine, a leading molecular insights company that recently received FDA approval for its FoundationOne CDx™ genomic test

The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the unanimous election of Mr. Peter Hardwick, Chief Commercial Officer and Executive Vice President of Apotex, as Chair of CGPA.